The Antimanic Effect of Endoxifen in Patients with Bipolar Disorder with Renal Comorbidities: Case Series
Open Access
- 21 September 2024
- journal article
- research article
- Published by SAGE Publications in Indian Journal of Psychological Medicine
Abstract
The conventional and standard pharmacological approaches in the management of bipolar disorders include mood stabilizers and second-generation antipsychotics. However, renal problems owing to the gold standard mood stabilizer, lithium, is three times that of the general population. As bipolar I disorder (BPD I) is associated with overactive protein kinase C (PKC) intracellular signaling, a novel approach in the management of acute mania/mixed affective states of bipolar disorder includes the use of PKC inhibitors, such as Tamoxifen and its derivative metabolite molecule, Endoxifen. Our objective is to report two cases of bipolar disorder that presented in acute manic episodes, with preexisting renal disease, and safe use of Endoxifen as an adjunct/monotherapy for rapid control of symptoms. According to our study, Endoxifen can be used as an anti-manic agent, either as monotherapy or as an adjunct, in patients with renal disease. It can also be used as an effective cover therapy for bipolar disorder patients requiring steroids for the treatment of renal pathology, though long-term studies are needed to assess the long-term safety and efficacy.Keywords
This publication has 14 references indexed in Scilit:
- Efficacy and safety of endoxifen in bipolar disorder: A systematic reviewHuman Psychopharmacology: Clinical and Experimental, 2024
- Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancernpj Breast Cancer, 2023
- Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorderBipolar Disorders, 2020
- Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenExpert Review of Clinical Pharmacology, 2019
- Risperidone‐Induced Renal Damage and Metabolic Side Effects: The Protective Effect of ResveratrolOxidative Medicine and Cellular Longevity, 2017
- Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of EndoxifenClinical and Translational Science, 2016
- Comorbid medical illness in bipolar disorderThe British Journal of Psychiatry, 2014
- Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorderBioorganic & Medicinal Chemistry Letters, 2010
- Protein Kinase C Inhibition in the Treatment of ManiaArchives of General Psychiatry, 2008
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978